News

Filter

Current filters:

Merck & CoAnti-virals

1 to 9 of 68 results

More EMA/CHMP recommendations

23-01-2015

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval…

Anti-viralsAntibiotics and Infectious diseasesCubistDutrebisEuropeIkervisMerck & CoOphthalmicsPharmaceuticalSanten PharmaceuticalsSivextro

Merck & Co drops marketing of hepatitis C drug Victrelis in USA

Merck & Co drops marketing of hepatitis C drug Victrelis in USA

22-01-2015

In an open letter to pharmacy professions, US pharma giant Merck & Co has advised that it is voluntarily…

Anti-viralsMarkets & MarketingMerck & CoPharmaceuticalUSAVictrelis

Merck & Co inks discovery and development deal with Moderna

Merck & Co inks discovery and development deal with Moderna

13-01-2015

Privately-held Moderna Therapeutics has entered into a license and collaboration agreement with US pharma…

Anti-viralsBiotechnologyFinancialMerck & CoModerna TherapeuticsResearchUSAVaccines

Merck & Co updates on plans to accelerate new drug submissions and future growth

Merck & Co updates on plans to accelerate new drug submissions and future growth

13-01-2015

US pharma giant Merck & Co has reported on the ongoing execution of its multi-year, strategic initiative…

Anti-viralsgrazoprevir/elbasvirKeytrudaMerck & CoOncologyPharmaceuticalRegulationResearchUSA

NewLink Genetic and Merck Ebola collaboration gets $30 million government award

23-12-2014

US biotech firm NewLink Genetics saw its shares gain 4.1% to $40.11 in morning trading on Monday, following…

Anti-viralsBiotechnologyFinancialMerck & CoNewLink GeneticsResearchTropical diseasesUSA

Merck and NewLink Ebola vaccine trial suspended as patients report joint pain

Merck and NewLink Ebola vaccine trial suspended as patients report joint pain

12-12-2014

Pharma giant Merck & Co’s Phase I trial of Ebola Vaccine VSV-ZEBOV, developed in conjunction with NewLink,…

Anti-viralsMerck & CoNewLink GeneticsPharmaceuticalResearchSwitzerland

Merck Ebola vaccine is well-tolerated by volunteers in early trials

Merck Ebola vaccine is well-tolerated by volunteers in early trials

02-12-2014

The Ebola vaccine developed by pharma giant Merck & Co and NewLink has been well-tolerated by trial volunteers…

Anti-viralsMerck & CoNewLink GeneticsPharmaceuticalResearch

Merck gains rights to NewLink Genetics investigational Ebola vaccine

24-11-2014

US pharma giant Merck & Co has entered into an exclusive worldwide license agreement to research, develop,…

Anti-viralsBiotechnologyGlobalLicensingMerck & CoNewLink GeneticsResearchrVSV-EBOYTropical diseases

1 to 9 of 68 results

COMPANY SPOTLIGHT

Menarini

Back to top